Communiqués Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R3030

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 26/06/2024			Varia. 5j.	Varia. 1 janv.
0,9319 ^USD	+1,29%		-39,09%	-46,44%

20/06	Les plus fortes baisses du jour	MT
13/06	Sonnet BioTherapeutics Holdings, Inc. annonce la génération et la caractérisation de deux nouveaux candidats médicaments immunothérapeutiques, SON-1411 et SON-1400, contenant chacun une variante du domaine IL-18	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds	20/06	GL
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain	13/06	GL
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting	28/05	GL
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting	28/05	AQ
Sonnet BioTherapeutics Announces Review of Strategic Alternatives	23/05	AQ
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target	21/05	AQ
Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K	20/05	PU
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference	03/05	NE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting	20/03	AQ
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers	01/03	AQ
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update	15/02	AQ
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy	22/12	AQ
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update	15/12	AQ
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering	26/10/23	AQ
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society Annual Meeting	18/10/23	AQ
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology	21/09/23	AQ
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance	20/09/23	AQ
Sonnet BioTherapeutics : Modification to Rights of Security Holders - Form 8-K	01/09/23	PU
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split	01/09/23	AQ
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update	15/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R3030

Communiqués

Filtres